For the quarter ended March 2026, Pfizer (PFE Quick QuotePFE - Free Report) reported revenue of $14.45 billion, up 5.4% over the same period last year. EPS came in at $0.75, compared to $0.92 in the year-ago quarter.

The reported revenue represents a surprise of +4.56% over the Zacks Consensus Estimate of $13.82 billion. With the consensus EPS estimate being $0.71, the EPS surprise was +5.63%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Specialty Care- Enbrel- Total International: $138 million versus $128.1 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.4% change.
• Revenues- Oncology- Talzenna- Total International: $14 million versus $14.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +27.3% change.
• Revenues- Oncology- Inlyta- Total International: $101 million versus the two-analyst average estimate of $62.1 million. The reported number represents a year-over-year change of +12.2%.
• Revenues- Specialty Care- Xeljanz- United States: $81 million versus the two-analyst average estimate of $52.5 million. The reported number represents a year-over-year change of +305%.
• Revenues- Oncology- Ibrance- Worldwide: $1.01 billion versus $944.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.2% change.
• Revenues- Specialty Care- Xeljanz- Worldwide: $180 million compared to the $148.62 million average estimate based on two analysts. The reported number represents a change of +40.6% year over year.
• Revenues- Specialty Care- Inflectra- Worldwide: $182 million versus the two-analyst average estimate of $124.19 million. The reported number represents a year-over-year change of +19%.
• Revenues- Primary Care- Eliquis- Worldwide: $2.17 billion versus $1.85 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +12.6% change.
• Revenues- Pfizer CentreOne- Worldwide: $289 million compared to the $260.55 million average estimate based on two analysts. The reported number represents a change of +12.5% year over year.
• Revenues- Pfizer Biopharma- Worldwide: $14.16 billion versus $13.52 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
• Revenues- Specialty Care- Vyndaqel family- Worldwide: $1.6 billion versus the two-analyst average estimate of $1.66 billion. The reported number represents a year-over-year change of +7.8%.
• Revenues- Primary Care- Comirnaty- Worldwide: $232 million versus $411.27 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -58.9% change.

View all Key Company Metrics for Pfizer here>>>

Shares of Pfizer have returned -5.5% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.